Index S&P 500
P/E 48.02
EPS (ttm) 3.36
Insider Own 0.11%
Shs Outstand 1.77B
Perf Week -0.89%
Market Cap 284.80B
Forward P/E 13.38
EPS next Y 12.05
Insider Trans -19.21%
Shs Float 1.76B
Perf Month -0.62%
Income 5.95B
PEG 7.88
EPS next Q 3.05
Inst Own 72.15%
Short Float 0.82%
Perf Quarter -6.81%
Sales 54.40B
P/S 5.23
EPS this Y 1.13%
Inst Trans 0.10%
Short Ratio 2.56
Perf Half Y 16.84%
Book/sh 4.53
P/B 35.57
EPS next Y 7.25%
ROA 4.20%
Short Interest 14.48M
Perf Year 10.02%
Cash/sh 10.23
P/C 15.76
EPS next 5Y 6.09%
ROE 55.92%
52W Range 130.96 - 182.89
Perf YTD 4.07%
Dividend Est. 6.25 (3.87%)
P/FCF 13.03
EPS past 5Y -5.77%
ROI 8.29%
52W High -11.82%
Beta 0.59
Dividend TTM 6.06 (3.76%)
Quick Ratio 0.83
Sales past 5Y 11.76%
Gross Margin 68.99%
52W Low 23.15%
ATR (14) 3.06
Dividend Ex-Date Apr 12, 2024
Current Ratio 0.94
EPS Y/Y TTM -21.01%
Oper. Margin 31.87%
RSI (14) 40.04
Volatility 1.16% 1.86%
Employees 50000
Debt/Eq 9.24
Sales Y/Y TTM -4.12%
Profit Margin 10.94%
Recom 1.97
Target Price 182.92
Option/Short Yes / Yes
LT Debt/Eq 7.97
EPS Q/Q 496.96%
Payout 220.33%
Rel Volume 0.61
Prev Close 160.75
Sales Surprise 3.19%
EPS Surprise 2.24%
Sales Q/Q 0.70%
Earnings Apr 26 BMO
Avg Volume 5.66M
Price 161.28
SMA20 -1.33%
SMA50 -5.91%
SMA200 2.11%
Trades
Volume 3,450,271
Change 0.33%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Upgrade
William Blair
Mkt Perform → Outperform
Dec-18-23 Downgrade
HSBC Securities
Buy → Hold
Dec-11-23 Upgrade
Goldman
Neutral → Buy
Nov-09-23 Initiated
Deutsche Bank
Hold
$150
Oct-30-23 Upgrade
Barclays
Equal Weight → Overweight
$160 → $170
Oct-20-23 Resumed
UBS
Neutral
$157 → $150
Sep-29-23 Initiated
Raymond James
Outperform
$177
Jul-25-23 Initiated
William Blair
Mkt Perform
Jul-14-23 Initiated
HSBC Securities
Buy
$167
Apr-05-23 Downgrade
Argus
Buy → Hold
Mar-01-23 Initiated
Guggenheim
Buy
$172
Feb-22-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Feb-10-23 Upgrade
SVB Securities
Underperform → Market Perform
$135 → $153
Nov-18-22 Initiated
Credit Suisse
Outperform
$170
Nov-08-22 Downgrade
Societe Generale
Buy → Hold
Aug-01-22 Downgrade
Atlantic Equities
Overweight → Neutral
$178 → $162
May-23-22 Initiated
SVB Leerink
Underperform
$140
May-06-22 Downgrade
Daiwa Securities
Outperform → Neutral
$150
Apr-06-22 Resumed
Morgan Stanley
Overweight
$192
Feb-28-22 Downgrade
UBS
Buy → Neutral
$129 → $147
Show Previous Ratings
May-13-24 04:51PM
11:44AM
11:09AM
09:34AM
08:39AM
08:38AM
Loading…
May-11-24 08:38AM
03:50AM
May-10-24 12:59PM
09:30AM
May-09-24 03:53PM
07:11AM
(Thomson Reuters StreetEvents)
May-08-24 02:10PM
10:49AM
09:37AM
08:32AM
08:00AM
Loading…
08:00AM
May-07-24 04:30PM
02:50PM
02:04PM
10:24AM
May-06-24 02:30PM
08:38AM
08:00AM
May-05-24 01:44PM
May-04-24 01:01AM
May-03-24 12:38PM
May-02-24 12:11PM
03:01AM
(Pharmaceutical Technology)
May-01-24 01:46PM
01:46PM
09:00AM
Loading…
09:00AM
Apr-30-24 01:50PM
12:02PM
11:45AM
08:38AM
08:00AM
06:32AM
Apr-29-24 04:06PM
(Investor's Business Daily)
11:24AM
08:37AM
08:24AM
Apr-28-24 06:54PM
06:49PM
07:17AM
04:20AM
Apr-27-24 07:15AM
03:07AM
01:24AM
(Thomson Reuters StreetEvents)
Apr-26-24 05:31PM
04:08PM
(Investor's Business Daily)
04:07PM
03:15PM
03:04PM
01:30PM
01:04PM
12:10PM
11:52AM
11:02AM
(Pharmaceutical Technology)
11:02AM
10:30AM
09:58AM
09:16AM
09:11AM
09:03AM
(Investor's Business Daily)
08:45AM
08:07AM
08:06AM
07:44AM
07:43AM
(Associated Press Finance)
07:36AM
07:35AM
07:00AM
Apr-25-24 04:48PM
10:58AM
08:44AM
08:15AM
08:00AM
Apr-23-24 03:09PM
12:38PM
12:14PM
09:15AM
08:00AM
Apr-22-24 12:56PM
09:47AM
Apr-21-24 07:00AM
Apr-19-24 04:11PM
(Investor's Business Daily)
10:00AM
Apr-18-24 03:44PM
12:18PM
(The Wall Street Journal)
08:31AM
06:30AM
Apr-17-24 05:45PM
Apr-16-24 10:21AM
10:01AM
09:00AM
08:00AM
03:06AM
03:02AM
Apr-15-24 07:57AM
07:43AM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Mar 20 '24 Sale 176.30 21,082 3,716,757 55,903 Mar 22 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Option Exercise 61.36 26,110 1,602,110 119,890 Mar 20 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Sale 178.79 58,949 10,539,508 60,941 Mar 20 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Option Exercise 61.36 45,700 2,804,152 89,517 Mar 05 05:30 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Sale 177.27 75,680 13,415,503 13,837 Mar 05 05:30 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Option Exercise 58.30 21,560 1,257,012 167,524 Mar 01 05:50 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Sale 176.45 68,879 12,153,957 98,645 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 29 '24 Sale 177.39 9,891 1,754,555 10,397 Mar 01 05:50 PM Buckbee Kevin K SVP, CONTROLLER Feb 29 '24 Sale 176.65 5,144 908,688 6,983 Mar 01 05:50 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Feb 28 '24 Sale 177.27 138,616 24,572,458 519,099 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Option Exercise 137.36 13,753 1,889,115 41,926 Feb 27 05:10 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Option Exercise 61.36 14,140 867,630 41,205 Mar 01 05:50 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Sale 177.44 14,140 2,509,002 27,065 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Sale 177.51 13,753 2,441,295 28,173 Feb 27 05:10 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Option Exercise 58.88 52,870 3,112,986 296,814 Feb 23 05:00 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Sale 173.71 52,870 9,184,048 243,944 Feb 23 05:00 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Dec 26 '23 Sale 154.72 2,912 450,545 55,903 Dec 28 05:00 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Aug 01 '23 Sale 148.58 60,000 8,914,800 565,294 Aug 02 05:07 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Jul 31 '23 Sale 149.15 18,500 2,759,275 625,294 Aug 02 05:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite